CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Elaprase Idursulfase Mucopolysarccharidosis II (MPS II), Hunter Syndrome Do not list Complete
Elelyso Taliglucerase alfa Gaucher disease Do not list Complete
Eliquis Apixaban Venous thromboembolic events, prevention List with clinical criteria and/or conditions Complete
Eliquis Apixaban Thromboembolic events prevention, (atrial fibrillation) List with clinical criteria and/or conditions Complete
Eliquis Apixaban Venous thromboembolic events, treatment and prevention of recurrence List with clinical criteria and/or conditions Complete
Elrexfio elranatamab Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Active
Emend Aprepitant Nausea and Vomiting, Chemotherapy induced List with clinical criteria and/or conditions Complete
Emgality galcanezumab Episodic cluster headache Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Emgality galcanezumab Prevention of migraine Reimburse with clinical criteria and/or conditions Complete
Empaveli pegcetacoplan Paroxysmal nocturnal hemoglobinuria Reimburse with clinical criteria and/or conditions Complete
Last Updated : July 27, 2024